文献速递细菌感染、耐药与抗菌药物

利奈唑胺与万古霉素抗MRSA的PKPD模型转化研究

Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time-kill experiments to a mouse pneumonia model.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

体内杀菌速率较体外低70%-75%,模拟显示标准给药方案下MIC低于临床折点菌株在24小时达细菌静止。

要点

  • 体内杀菌速率较体外低70%-75%
  • 两种药物使小鼠肺内菌量较对照下降最多2个log
  • 标准给药方案下MIC低于折点菌株24小时达静止

核心结论

  • 基于体外和体内数据的PKPD模型可表征利奈唑胺与万古霉素暴露后的细菌动力学,该转化工作流程可为抗生素开发提供信息。
  • 首次成功将标准化小鼠肺炎模型用于革兰阳性菌研究。

研究设计与样本

  • 使用人体PK进行模拟以预测患者抗菌反应。

主要发现

  • 体外暴露于万古霉素浓度时观察到的细菌再生长由适应性耐药模型描述。
  • 所选MRSA分离株在小鼠肺炎模型中显示出良好毒力。
  • 利奈唑胺和万古霉素治疗后小鼠肺内细菌载量较对照小鼠下降最多2个log。
  • 体内数据估计的杀菌速率较体外低70%-75%。
  • 模拟显示,对于MIC低于两种药物临床折点的细菌感染患者,给予标准治疗给药方案后24小时达细菌静止。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: MRSA is one of the main pathogens that cause nosocomial pneumonia. Based on longitudinal in vitro and in vivo data, a pharmacokinetic-pharmacodynamic (PKPD) model was built to quantify the effect of two control antibiotics (LZD and VAN) for Gram-positive bacteria in a standardized mouse pneumonia model. METHODS: The PKPD model was developed for data generated on the MRSA strain 160 079 in static in vitro time-kill experiments and thereafter adjusted to fit data from lungs of neutropenic mice administered with single or multiple doses of LZD (0.5-40 mg/kg) or VAN (1-40 mg/kg). Simulations with human PK were run to predict antibacterial response in patients. RESULTS: Bacterial regrowth observed in vitro when exposed to VAN concentrations was described by an adaptive resistance model. The selected MRSA isolate showed good virulence in the mouse pneumonia model. Bacterial load in lungs decreased up to 2-log with respect to control mice after LZD and VAN treatment. A 70%-75% lower killing rate was estimated for the in vivo data when compared with in vitro. Simulations displayed bacterial stasis at 24 h for patients infected with bacteria with MICs below the clinical breakpoint for both drugs after administering standard-of-care dosing regimens. CONCLUSIONS: A translational workflow allowed us to build a PKPD model with both in vitro and in vivo data that characterized bacterial dynamics following LZD and VAN exposure, showing that this approach can inform the development of antibiotics. We also showcased the first successful use of the standardized mouse pneumonia model for Gram-positive bacteria.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Vera-Yunca D, Matias C, Vingsbo Lundberg C, et al. Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time-kill experiments to a mouse pneumonia model. J Antimicrob Chemother. 2025. PMID: 40343749. doi:10.1093/jac/dkaf140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。